Open Actively Recruiting

Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis

About

Brief Summary

This study is a prospective observational study for subjects with idiopathic pulmonary fibrosis (IPF) or non-IPF interstitial lung diseases (ILD).

The purpose of this study is to compare whether imaging patterns from high-resolution computed tomography (HRCT) at baseline can predict worsening. Single Time point Prediction (STP) is a score derived from an artificial intelligenc/ machine learning (AI/ML) using the radiomic features from a HRCT scan that quantifies the imaging patterns of short-term predictive worsening.

Study Type
Observational
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
18 Years
Maximum Age
N/A

IPF Inclusion Criteria:

  • Established a diagnosis (within 3 years) of IPF by enrolling center as defined by ATS/ERS/JRS/ALAT criteria
  • Age over or equal to 40 years old
  • No history of lung transplant
  • FVC % predicted >= 45%
  • DLCO % predicted >=25%

Non-IPF ILD Inclusion Criteria:

  • Established a diagnosis (within 3 years) of IPF by enrolling center.
  • Age over or equal to 18 years old
  • Presence of chronic fibrosis ILD defined as architectural distortions with reticulation and the presence of traction bronchiectasis estimating visually >10% in whole lung.
  • FVC % predicted >= 45%
  • DLCO % predicted >=25%

Exclusion Criteria:

  • Planned to participate an intervention trial within the next 3 months
  • Currently listed for lung transplantation at the time of enrollment
  • Malignancy, treated or untreated, other than skin cancer or prostate cancer within the past 5 years
  • Exclusion of co-morbidities: congestive heart failure (stroke, deep vein thrombosis, pulmonary embolism, myocardial infarction), current virus-associated community acquired pneumonia, smoking-related chronic obstructive lung disease with FEV1 < 70%, history of lung cancer, history of other cancer treated within the past 4 years (excluding basal cell carcinoma of skin). HRCT data from subjects with combined pulmonary fibrosis and emphysema (CPFE) can be collected. Major Discontinuing Criteria in this study
  • lung transplant after baseline or death
  • withdraw of consent or transition to another care center

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Share:
Study Stats
Protocol No.
23-001246
Category
Lung/Respiratory Disorders
Principal Investigator
GRACE HYUN KIM
Contact
Claudia Perdomo
Location
  • UCLA Westwood
For Providers
NCT No.
NCT06162884
For detailed technical eligibility, visit ClinicalTrials.gov.